Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Women with polycystic ovary syndrome (PCOS) are characterized by defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis. We administered the insulin-sensitizing agent troglitazone to 13 obese women with PCOS and impaired glucose tolerance to determine whether attenuation of hyperinsulinemia ameliorates these defects. All subjects had oligomenorrhea, hirsutism, polycystic ovaries, and hyperandrogenemia. Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the beta-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator]. There was no change in body mass index (39.9 +/- 1.4 vs. 40.2 +/- 1.4 kg/m2) or body fat distribution after treatment. Both the fasting (91 +/- 3 vs. 103 +/- 3 mg/dL; P < 0.001) and 2 h (146 +/- 8 vs. 171 +/- 6 mg/dL; P < 0.02) plasma glucose concentrations during the oral glucose tolerance test declined significantly. There was a concordant reduction in glycosylated hemoglobin to 5.7 +/- 0.1 from a pretreatment level of 6.1 +/- 0.1% (P < 0.03). Insulin sensitivity increased from 0.58 +/- 0.14 to 0.95 +/- 0.26 10(-5) min-1/pmol.L (P < 0.01) after treatment as did the disposition index (745 +/- 135 vs. 381 +/- 96; P < 0.05). The ability of the beta-cell to appropriately detect and respond to an oscillatory glucose infusion improved significantly after troglitazone treatment; the normalized spectral power for the insulin secretion rate increased to 5.9 +/- 1.1 from 4.3 +/- 0.8 (P < 0.05). Basal levels of total testosterone (109.3 +/- 15.2 vs. 79.4 +/- 9.8 ng/dL; P < 0.05) and free testosterone (33.3 +/- 4.0 vs. 21.2 +/- 2.6 pg/mL; P < 0.01) declined significantly after troglitazone treatment. Leuprolide-stimulated levels of 17-hydroxyprogesterone, androstenedione, and total testosterone were significantly lower posttreatment compared to pretreatment. The reduction in androgen levels occurred independently of any changes in gonadotropin levels. A decreased functional activity of PAI-1 in blood (from 12.7 +/- 2.8 to 6.3 +/- 1.4 AU/mL P < 0.05) was associated with a decreased concentration of PAI-1 protein (from 64.9 +/- 9.1 to 44.8 +/- 6.1 ng/mL; P < 0.05). No change in the functional activity of tissue plasminogen activator (from 5.3 +/- 0.4 to 5.1 +/- 0.5 IU/mL) was observed despite a decrease in its concentration (from 9.6 +/- 0.9 to 8.2 +/- 0.7 ng/mL; P < 0.05). The marked reduction in PAI-1 could be expected to improve the fibrinolytic response to thrombosis in these subjects. We conclude that administration of troglitazone to women with PCOS and impaired glucose tolerance ameliorates the metabolic and hormonal derangements characteristic of the syndrome. Troglitazone holds potential as a useful primary or adjunctive treatment for women with PCOS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low SHBG levels are also increased by insulin-sensitising medication (Ehrmann et al., 1997;Moghetti et al., 2000;Moran et al., 2013);”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Ehrmann et al., 1997
Citations
Cites
Spectral Analysis and its Applications.
Freiberger, W. F., Jenkins, G. M., & Watts, D. G. (1969) · Journal of the American Statistical Association · doi:10.2307/2286100 · Cited by 4,981
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Morgan, C. R., & Lazarow, A. (1963) · Diabetes · doi:10.2337/diab.12.2.115 · Cited by 2,199
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 2×
“It is important to note, however, that although insulin sensitivity improved in response to treatment, it remained profoundly depressed in these subjects and was disproportionate to the degree of obesity, as described previously ( 2 ).”
BackgroundBergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640 · cited 3×
“Because the product of these measures is presumed to be constant ( 33 , 42, 43), a compensatory decrease in AIRg would be expected to accompany the increase in Si observed after troglitazone treatment.”
BackgroundMethodInfluentialMazess, R., Barden, H., Bisek, J., & Hanson, J. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.6.1106 · Cited by 1,476
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 4×
“The product of Si and AIRg (disposition index) was also derived and provides a measure of b-cell secretory function adjusted for insulin sensitivity, previously described as a constant in any individual ( 43 ).”
BackgroundMethodInfluentialThiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053 · cited 1×
“Although the precise mechanism of action of troglitazone remains incompletely defined, it appears to enhance insulin action without directly stimulating insulin secretion ( 50 ) and acts as a selective ligand for the peroxisome proliferator-activated receptor-g (51).”
BackgroundToward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Cited by
Items 401–485 of 485
Effects of thiazolidinediones on cardiovascular risk factors
Gouda, B. P., Asnani, S., & Fonseca, V. A. (2002) · Comprehensive Therapy · doi:10.1007/s12019-002-0018-8 · Cited by 4
Advances in the treatment of polycystic ovary syndrome
Moghetti, P. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.9.1631 · Cited by 4
Management of Polycystic Ovary Syndrome
Yasmin, E., & Balen, A. H. (2007) · Women s Health · doi:10.2217/17455057.3.3.355 · Cited by 4
Thiazolidinediones: Benefits and risks
Hernández-Jiménez, S. C., Aguilar-Salinas, C. A., & Gomez-Perez, F. J. (2002) · Revista de Endocrinología y Nutrición · Cited by 9
Diamanti‐Kandarakis, E. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-310-3_32 · Cited by 4
Attenuation of hyperinsulinemia in polycystic ovary syndrome: What are the options?
Ehrmann, D. A. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03350790 · Cited by 4
Self-citationToward a new approach: primary and preventive care of the woman with polycystic ovarian syndrome
Ahles, B. L. (2000) · Primary Care Update for OB/GYNS · doi:10.1016/s1068-607x(00)00059-7 · Cited by 4
Insulin Sensitizers Targeting Metabolic and Reproductive Consequences in Polycystic Ovary Syndrome
Diamanti‐Kandarakis, E. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-108-6_13 · Cited by 3
Tamura, K., Osada, S., Matsushita, M., Abe, K., & Kogo, H. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.02.048 · Cited by 3
Cobin, R. H. (2005) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2005.3.259 · Cited by 3
PPARγ Agonists and Vascular Risk Factors: Potential Effects on Cardiovascular Disease
Asnani, S., Theuma, P., & Fonseca, V. A. (2003) · Metabolic Syndrome and Related Disorders · doi:10.1089/154041903321648234 · Cited by 3
The link between polycystic ovary syndrome and Type 2 diabetes: what do we know today?
Sathyapalan, T., & Atkin, S. L. (2011) · Diabetes Management · doi:10.2217/dmt.11.59 · Cited by 4
Zhong, W., Peng, H., Li, H., Shang, H. F., Wei, Y.-Q., Fang, Z., & Zhao, X. (2016) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v14i12.19 · Cited by 4
Azziz, R. (2007) · Springer eBooks · doi:10.1007/978-0-387-69248-7_8 · Cited by 4
Polycystic Ovarian Syndrome: Pathophysiology and Infertility
Alsadi, B. (2014) · World Journal of Laparoscopic Surgery with DVD · doi:10.5005/jp-journals-10007-1212 · Cited by 3
Insulin-Sensitizing Drugs for the Treatment of Infertility in Polycystic Ovary Syndrome
Ryan, C. S., & Nestler, J. E. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-310-3_10 · Cited by 4
New routes in the polycystic ovary syndrome labyrinth: A way out?
Moghetti, P., & Castello, R. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03350793 · Cited by 3
Marx, N., & Hombach, V. (2001) · Zeitschrift für Kardiologie · doi:10.1007/s003920170135 · Cited by 8
How best to counteract the enemies? By controlling inflammation in the coronary circulation
Kluft, C. (2002) · European Heart Journal Supplements · doi:10.1016/s1520-765x(02)90090-8 · Cited by 3
Síndrome del ovario poliquístico: nuevas perspectivas
Pazos, F., & Rodríguez-Caballero, A. (2004) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(04)74657-4 · Cited by 5
Polycystic Ovary Syndrome, Pathophysiology, and Reproductive Health Implications
Alsadi, B. (2018) · InTech eBooks · doi:10.5772/intechopen.70848 · Cited by 2
Menstrual Disorders and Hyperandrogenism in Adolescence
DiVall, S. A., & Rosenfield, R. L. (2013) · Humana Press eBooks · doi:10.1007/978-1-60761-395-4_25 · Cited by 2
Self-citationAmerican Association of Clinical Endocrinologists Meeting, May 2002
Bloomgarden, Z. T. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1464 · Cited by 3
Insulin Resistance in Children and in the Polycystic Ovarian Syndrome
Bloomgarden, Z. T. (2005) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2005.3.294 · Cited by 2
Praktisches Vorgehen bei gestörter Ovarfunktion und damit assoziierten Phänomenen
Strowitzki, T. (2009) · Springer eBooks · doi:10.1007/978-3-540-89760-6_24 · Cited by 5
Amowitz, L. L., Manson, J. E., & Ridker, P. M. (2000) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1026539006624 · Cited by 2
Peroxisome proliferator-activated receptor (PPAR) isoforms in coronary heart disease
Yılmaz, H., Kurt, O., Kurnaz, Ö., Teker, B. A., & Küçükhüseyin, Ö. (2013) · Turkish Journal of Biochemistry · doi:10.5505/tjb.2013.08760 · Cited by 9
Lifestyle factors in the etiology and management of polycystic ovary syndrome
Norman, R. J., & Moran, L. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545191.009 · Cited by 2
Fetal Origins of Polycystic Ovary Syndrome
Abbott, D. H., Bruns, C. M., Barnett, D. K., Tarantal, A. F., Hoffmann, S. M., Zhou, R., Levine, J. E., & Dumesic, D. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-108-6_6 · Cited by 3
Zhou, R., Bruns, C. M., Bird, I. M., Kemnitz, J. W., Dumesic, D. A., & Abbott, D. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052635 · Cited by 2
Polycystic ovary syndrome: What is it? Pathogenetic enigma and therapeutic dilemma
Toscano, V. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03350779 · Cited by 2
Halikias, I., Lytras, A., Syriou, V., & Tolis, G. (1997) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625189709165297 · Cited by 2
Cost-effective therapy in patients with idiopathic hirsutism
Lumachi, F., Zulian, E., & Scaroni, C. M. (2004) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.4.3.297 · Cited by 2
Insulin resistance in polycystic ovary syndrome
Morin-Papunen, L. C. (2000) · Cited by 3
Baillargeon, J., & Farid, N. R. (2009) · Springer eBooks · doi:10.1007/978-0-387-09718-3_18 · Cited by 2
Praktisches Vorgehen bei gestörter Ovarfunktion und mit ihr assoziierter Phänomene
Strowitzki, T. (2005) · Springer eBooks · doi:10.1007/3-540-26406-x_23 · Cited by 2
Schneider, D. J., & Sobel, B. E. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-091-9_9 · Cited by 4
Self-citationDiet and Lifestyle Factors in the Etiology and Management of Polycystic Ovary Syndrome
Norman, R. J., & Moran, L. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-310-3_11 · Cited by 1
Pharmacologic Approaches to Type 2 Diabetes and Obesity in Children and Adolescents
Pongsuwan, P. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-256-8_12 · Cited by 1
Kelley, C. E., Brown, A. J., & Setji, T. L. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.941814 · Cited by 1
Fuel Sensor PPARγ: a Potential Gateway for Fertility Regulation in Buffalo
Singh, D., Sharma, I., & Onteru, S. K. (2013) · Buffalo Bulletin · Cited by 1
Sobel, B. E. (2015) · Cardiovascular medicine · doi:10.1007/978-1-4471-2828-1_6 · Cited by 2
Self-citationInsulin-Sensitizing and Insulin-Sparing Drugs: Thiazolidinediones and Metformin
Jabbour, S. A. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-0273-4.50029-1 · Cited by 2
Revisiting Hormonal profile in PCOS in Adolescents and Young Women
Bera, A., Bagchi, B., & Chatterjee, S. (2025) · Medical Research Archives · doi:10.18103/mra.v13i4.6430 · Cited by 2
Martinez, A. M., & Lindheim, S. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6837-0_14 · Cited by 1
The Risks of Cardiovascular Disease and Diabetes in the Polycystic Ovary Syndrome
Sharma, S. T., & Nestler, J. E. (2009) · Springer eBooks · doi:10.1007/978-0-387-09718-3_10 · Cited by 2
Obesity in Polycystic Ovary Syndrome: Two Diseases or One?
Salehi, M., Vera, R. B., Sheikh, A., Gouller, A., & Poretsky, L. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
THE GENETICS OF INSULIN RESISTANCE IN FAMILIES WITH POLYCYSTIC OVARY SYNDROME
Matar, J. (2006) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 2
C-Peptide Profiling and Type 2 Diabetes Treatment Decisions
Braithwaite, S. S. (1999) · Endocrine Practice · doi:10.4158/ep.5.6.371 · Cited by 1
Thiazolidinediones in Cardiovascular Risk in Type 2 Diabetes Mellitus
Khamaisi, M., Symer, L., & Raz, I. (2003) · Springer eBooks · doi:10.1007/978-3-642-59352-9_17 · Cited by 1
Polycystic Ovary Syndrome, Obesity and Insulin Resistance
Cassar, S. (2014) · Victoria University Research Repository (Victoria University) · Cited by 1
Therapeutic Aspects of Polycystic Ovary Syndrome in Adolescence
Koliopoulos, C., & Creatsas, G. K. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-310-3_27 · Cited by 1
Marx, N. (2002) · Journal für Kardiologie (Krause & Pachernegg GmbH)
La sindrome dell’ovaio policistico
Toscano, V. (2000) · L Endocrinologo · doi:10.1007/bf03344362
Plutzky, J. (2008) · Wiley eBooks · doi:10.1002/9783527610754.md05
A 9-Year-Old Girl Presenting Central Precocious Puberty with Polycystic Ovary Syndrome.
Minamitani, K., Nakajima, H., Hoshioka, A., Tamai, K., Kurosaki, T., Matsumoto, R., Minagawa, M., & Kohno, Y. (2002) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.11.77
Toda, L. I., & Potau, N. (2001) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(01)74375-6
Carrera, M. V. (2005) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(05)73371-4
Is This Patient Insulin Resistant? How Much Does It Matter?
Sheeder, J. L., Travers, S. H., & Stevens–Simon, C. (2003) · Clinical Pediatrics · doi:10.1177/000992280304200911
Seminara, S. B., Hall, J. E., Taylor, A. E., Crowley, W. F., & Martin, K. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1912
Síndrome metabólico (Segunda Parte)
Isaac Crespo, R., Iván Odórico Belzusarri, P., & Aldo Stucchi, G. (2006) · Horizonte Médico (Lima) · doi:10.24265/horizmed.2006.v6n2.07
Síndrome de ovario poliquístico y enfermedad cardiovascular
Escalada, J. (2005) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(05)71021-4 · Cited by 2
Siebert, T. I. (2008) · SUNScholar (Stellenbosch University)
Ovaires micropolykystiques et syndrome d’insulinorésistance
LORCY, Y. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81683-x
Todorova-Ananieva, K., Konova, E. I., Iafusco, D., Palaveev, O., Emin, A., Atanasova, M., & Guenova, M. L. (2010)
Weiss, J. M., Diedrich, K., & Ortmann, O. (2002) · Der Gynäkologe · doi:10.1007/pl00003294
Sterilitätsbehandlung bei Patientinnen mit polyzystischem Ovarsyndrom (PCOS)
Strowitzki, T., & Hamann, A. (2002) · Der Gynäkologe · doi:10.1007/pl00003295
Polycystic Ovarian Disease: Gynaecological and Metabolic Implications
Tessier, J. L., & Reid, R. L. (1999) · Journal SOGC · doi:10.1016/s0849-5831(16)30472-4
Mechanisms by which Thiazolidinediones Enhance Insulin
Lazar, M. A. (1999)
Burton Elias Sobel, MD: a conversation with the editor
Be, S. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00892-3
Nutritional Strategies for Patients with Obesity and the Metabolic Syndrome
Kushner, R. F., & Roth, J. L. (2006) · Nutrition and disease prevention · doi:10.1201/9781420014884.ch4
Future Directions: Elucidation of Mechanisms as Targets for Therapy
Peragallo‐Dittko, V. (2002) · CRC Press eBooks · doi:10.1201/b14062-17
Polycystic Ovary Syndrome, Insulin Resistance and Cardiovascular Disease
Corcoran, M. H., & Ehrmann, D. A. (2002) · CRC Press eBooks · doi:10.1201/b14062-10
Self-citationGlukosetoleranz und Diabetes mellitus im Alter
Tragl, K. H. (1999) · Springer eBooks · doi:10.1007/978-3-7091-6409-9_11
Insulin Resistance in PCOS (Polycystic Ovary Syndrome)
Ehrmann, D. A. (2003) · Elsevier eBooks · doi:10.1016/b0-12-341103-3/00236-9
Self-citationZiouzenkova, O., Marx, N., Libby, P., & Plutzky, J. (2007) · Wiley eBooks · doi:10.1002/9780470988473.ch24
Anovulatory infertility and ovulation induction
(2008) · Reproductive medicine and assisted reproductive techniques series · doi:10.3109/9781439807224.007
(2002) · CRC Press eBooks · doi:10.1201/b14062-2
Bakhashab, S., Batarfi, A. A., Alhartani, M. M., Turki, R. F., & Mady, W. (2024) · Biomarker Insights · doi:10.1177/11772719241258585
“35 In our cohort, we found direct associations between APOA5 SNP rs662799 and PCOS susceptibility and hypertriglyceri-daemia among patients with PCOS.”
BackgroundHoughton, M. A., McCartney, C. R., Kim, S. H., Patrie, J. T., Marshall, J. C., & Solorzano, C. M. B. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf154 · Cited by 1
Insulin Sensitizers and Cardiovascular Disease
Thethi, T. K., Singh, S., & Fonseca, V. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-141-3_6
多毛, 月経異常, 肥満を伴った糖尿病にトログリタゾンが有用であった1例
小山, 一., 康洋, 斎., & 青木, 誠. (2000) · 医療 · doi:10.11261/iryo1946.54.235
Role of Estrogens in Vascular Disease in Diabetes
Tsatsoulis, A. A., & Economides, P. A. (2005) · Humana Press eBooks · doi:10.1385/1-59259-908-7:129
Metadata
- Authors
- Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S.
- Affiliations
- University of Chicago (US)
- University of Vermont (US)
- Corresponding author
- Ehrmann, David A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-07
- Volume
- 82
- Issue
- 7
- Pages
- 2108-2116
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2073637312
- Cited by
- 461
- References
- 67
- Citations by year
- 2025: 2 · 2024: 3 · 2022: 6 · 2021: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 2 · 2014: 5 · 2013: 10 · 2012: 11
- FWCI
- 36.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08dk002315-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- troglitazone, polycystic ovary syndrome, insulin resistance, insulin secretion, beta-cell function, ovarian steroidogenesis, fibrinolysis, plasminogen activator inhibitor-1, tissue plasminogen activator, hyperinsulinemia, impaired glucose tolerance, insulin sensitizers, hyperandrogenemia, obese women, leuprolide
- MeSH terms
- Troglitazone, Adult, Androgens, Chromans, Female, Fibrinolysis, Glucose, Glucose Tolerance Test, Gonadotropins, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Thiazoles, Leuprolide, Plasminogen Activator Inhibitor 1, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.